TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that patient enrollment has been initiated in the Phase 3 program evaluating the efficacy and safety of ARCALYST® (rilonacept), also known as IL-1 (interleukin-1) Trap, in the prevention of gout flares associated with the initiation of urate-lowering drug therapy and in the treatment of acute gout attacks. ARCALYST is approved in the U.S. for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.
